Retrobrands USA looking to bring Aspergum back to market
MAHWAH, N.J. – RJM Licensing, in partnership with Arabella Enterprises, on Wednesday announced they have been signed by Retrobrands USA to help bring back Aspergum, a chewable aspirin product indicated to soothe sore throats, control fevers and provide all over pain relief.
With Aspergum, consumers get a product that has 89 years of brand awareness in a flavored chewable tablet. "We feel that 2017 is the perfect year to reintroduce Aspergum to the 100 million baby boomers who fondly remember this iconic brand," stated Jeff Kaplan, president Retrobrands USA. "Have a cold or a sore throat? Grab a delicious chewable Aspergum."
RJM Licensing is a full service licensing agency specializing in the representation of books, brands and artists. And Arabella Enterprises is a branding and licensing agency dedicated to the development of multi-million dollar brand extension programs through licensing.
NBTY backs MET-Rx line extensions with extensive ad campaign
RONKONKOMA, N.Y. – NBTY on Wednesday unveiled three new lines of innovative products across its MET-Rx portfolio. In addition to the product innovation, the brand is launching a full packaging refresh and a national advertising campaign. To help bring this to life, MET-Rx has partnered with Joey Bosa, a collegiate defensive end and one of the top projected 2016 football prospects.
"We understand the hard work and dedication that goes into training; the blood, sweat and tears it takes to achieve athletic dominance," stated Brad Charron, SVP and general manager of MET-Rx. "The MET-Rx portfolio is designed to help athletes nourish and love their inner monster, and our new product lines were developed to meet the needs of a new generation of athletes and provide them with the necessary tools to get to the next level."
The three new products include:
- MET-Rx Super Hydrate Sports Drink is a ready to drink beverage that contains no artificial flavors, preservatives or sweeteners. Super Hydrate is made with 20% coconut water and contains the ideal ratio of all six essential electrolytes for hydration – potassium, sodium, calcium, phosphorus, chloride and magnesium. Super Hydrate contains lower sugar content than most leading sports drinks in the market and is available in four flavors, including lemon lime, orange mango, tropical punch and fruit punch;
- MET-Rx Ultra Recovery High Protein Milk Shake, available in chocolate and vanilla, is a post-workout protein shake made with real milk and contains no artificial colors, sweeteners, flavors or preservatives. Ultra Recovery Shake provides the recovery benefits of chocolate milk, with 39% less sugar per ounce, and also offers the ideal protein ratio to promote workout recovery; and
- The Sports Series Powders are formulated with no stimulants and are geared and developed for the specific needs of athletes training for their particular sport. The pre- and post-game powders are available in four flavors, including fruit punch, mango, iced tea and chocolate graham.
MET-Rx has tapped Big Ten Defensive Player of the Year Joey Bosa in a multi-year deal to serve as a brand spokesperson and advocate. In celebration of athletic achievement, Bosa will host a media event in Chicago on April 28 just prior to professional teams making their first round picks. At the event, Bosa will talk about his path to dominance, highlighting what it took to get to where he is today.
"This selection week represents the culmination of many years of intense preparation to perform and compete at the highest level, so this time is the perfect opportunity to align with our brand's purpose to champion complete athletic dominance and celebrate those who achieve it," Charron said. "Joey Bosa is a prime example of a young athlete who embraced his inner monster and channeled that passion into athletic success, which makes him a perfect fit for the MET-Rx brand. We are very excited to partner with him."
The MET-Rx launch event also marks the debut of the brand's new national advertising campaign, "Love the Monster." Created by Droga5, the new campaign celebrates athletic dominance, taking preparation and confidence to the field. The :15, :30 and :80 second spots, directed by Academy Award-winning documentary filmmakers TJ Martin and Dan Lindsey, follow a football player on his team bus as it rolls into a rival town, focusing on the preparation and energy needed to love the monster within and dominate on the field. The new spot marks the first national advertising campaign for the MET-Rx brand in decades.
Debuting on April 27, the new campaign includes TV spots on ESPN, followed by significant digital investments, including a video integration with Stack.com, paid search and unique social media content.
FDA approves 3 Aurobindo generics
SILVER SPRING, Md. — The Food and Drug Administration has approved three generics from Aurobindo Pharma this week — two prescription drugs and one OTC. On Tuesday, the agency approved Aurobindo’s generic Exforge (amlodipine and valsartan) tablets, and on Wednesday gave its OK to the company's generic Opana (oxymorphone HCl) and Pepcid AC (famotidine).
Exforge is indicated to treat hypertension and high blood pressure, with an estimated market size of $123 million for the 12 months ending February 2016, according to IMS Health. Aurobindo’s generic will be available in 5- and 10-mg amlodipine/160-mg valsartan and 5- and 10-mg amlodipine/320-mg valsartan dosage strengths. The company expects to launch its generic in the first quarter of FY16.
The company’s Opana generic is indicated to treat moderate to severe acute pain where opioid use is appropriate and according to IMS Health, the product had a market size of $55.5 million for the 12 months ending February 2016. It will be available in 5- and 1—mg dosage strengths.
Aurobindo’s generic of Pepcid AC will be available in 10- and 20-mg strength and be sold over the counter, with an expected launch in the second quarter of FY16. Its estimated market size, according to IMS Health, is about $31 million for the 12 months ended February 2016.
Loading Post Please Wait...